NanoViricides creates special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class drug candidates are designed to attack and dismantle enveloped virus particles. The company’s development candidates include anti-influenza injectable and oral drugs, which are expected to be effective against most types of influenza viruses. NanoViricides is also developing drugs against HIV, oral and genital herpes, viral diseases of the eye, and dengue viruses. For more information, visit the company’s website at www.nanoviricides.com.